Nephrology

🔬 Glomerular Architecture: The Kidney's Precision Filtration Network

You'll master the glomerulus as both an elegant biological filter and a clinical diagnostic gateway, learning how its three-layered architecture creates size- and charge-selective barriers that can fail in predictable patterns. We'll connect microscopic structure to pressure dynamics, then to the pathological signatures that distinguish nephritic from nephrotic syndromes at the bedside. By integrating histology, hemodynamics, and pattern recognition with evidence-based treatment algorithms, you'll build the systematic framework needed to diagnose glomerular disease confidently and intervene effectively across complex multi-system presentations.

The glomerular filtration barrier operates as a three-layer molecular sieve with distinct size and charge selectivity:

• Fenestrated Endothelium (Inner Layer)

  • Pore diameter: 70-100 nm
  • Blocks cellular elements (RBCs, WBCs, platelets)
  • Allows free passage of plasma proteins
    • Albumin (3.6 nm): 100% passage
    • Immunoglobulins: 95% passage
    • Fibrinogen: 90% passage

• Glomerular Basement Membrane (Middle Layer)

  • Thickness: 300-350 nm in adults
  • Composed of Type IV collagen, laminin, proteoglycans
  • Primary size-selective barrier
    • Albumin restriction: <5% normal passage
    • Larger proteins: <1% passage
  • Negative charge repels anionic proteins

• Podocyte Foot Processes (Outer Layer)

  • Slit diaphragm width: 4-14 nm
  • Contains nephrin, podocin, CD2AP proteins
  • Final charge-selective barrier
    • Maintains <150 mg/day protein excretion
    • Prevents albumin loss through charge repulsion

📌 Remember: GBM-FEN - Glomerular Basement Membrane, Fenestrated Endothelium, Nephrin (podocytes). Size selectivity increases from endothelium (100 nm) → GBM (3.6 nm albumin restriction) → podocytes (<1 nm effective pore size).

The mesangial compartment provides structural support and regulatory control:

• Mesangial Cells (8-10% of glomerular volume)

  • Contractile properties regulate capillary flow
  • Phagocytic function removes immune complexes
  • Produce extracellular matrix components
  • Respond to angiotensin II, endothelin, vasopressin

• Mesangial Matrix

  • Contains Type III collagen, fibronectin, proteoglycans
  • Expansion occurs in >80% of diabetic nephropathy cases
  • Increased deposition correlates with GFR decline

💡 Master This: Glomerular diseases follow predictable patterns based on which barrier component fails. Endothelial damage → acute nephritis with hematuria. GBM abnormalities → hereditary nephritis with progressive hearing loss. Podocyte injury → nephrotic syndrome with massive proteinuria >3.5 g/day.

Connect this architectural foundation through Glomerular Hemodynamics: The Pressure-Flow Control System to understand how structure enables the precise pressure regulation that maintains filtration across varying physiological conditions.

⚡ Glomerular Hemodynamics: The Pressure-Flow Control System

Starling Forces govern glomerular filtration through four pressure components:

• Glomerular Capillary Hydrostatic Pressure (PGC)

  • Normal range: 45-60 mmHg
  • Primary driving force for filtration
  • Maintained by afferent/efferent arteriolar resistance ratio
  • Decreases along capillary length: 60 mmHg (afferent) → 45 mmHg (efferent)

• Bowman's Space Hydrostatic Pressure (PBS)

  • Normal value: 10-15 mmHg
  • Opposes filtration
  • Elevated in urinary obstruction (>25 mmHg)
  • Increased in acute tubular necrosis due to cast formation

• Glomerular Capillary Oncotic Pressure (πGC)

  • Initial value: 25-30 mmHg
  • Increases along capillary: 30 mmHg → 35 mmHg
  • Opposes filtration
  • Reduced in hypoalbuminemia (<3.0 g/dL)

• Bowman's Space Oncotic Pressure (πBS)

  • Normal value: 0 mmHg (protein-free)
  • Becomes positive in proteinuric diseases
  • >1 mmHg indicates significant glomerular barrier damage

📌 Remember: PGBO - Pressure Glomerular (favors filtration), Bowman's pressure (opposes), Oncotic glomerular (opposes), Oncotic Bowman's (favors when proteinuric). Net filtration pressure = (PGC - PBS) - (πGC - πBS) = Normal 10-15 mmHg.

• Myogenic Response (Afferent Arteriole)

  • Responds to transmural pressure changes
  • Vasoconstriction when pressure >100 mmHg
  • Vasodilation when pressure <80 mmHg
  • Mediated by calcium channel activation
  • Preserved in >90% of healthy kidneys

• Tubuloglomerular Feedback (Juxtaglomerular Apparatus)

  • Macula densa senses NaCl delivery
  • High NaCl → adenosine release → afferent vasoconstriction
  • Low NaCl → renin release → efferent vasoconstriction
  • Response threshold: >40 mEq/L NaCl concentration
  • Impaired in diabetic nephropathy and hypertensive nephrosclerosis

⭐ Clinical Pearl: Autoregulation fails when mean arterial pressure drops below 80 mmHg or exceeds 180 mmHg. In these ranges, GFR becomes pressure-dependent, explaining why systolic BP >160 mmHg or <90 mmHg increases acute kidney injury risk by 2-3 fold.

Pharmacological Modulation of glomerular hemodynamics:

• ACE Inhibitors/ARBs

  • Preferentially dilate efferent arterioles
  • Reduce intraglomerular pressure by 10-15 mmHg
  • May decrease GFR by 20-30% initially
  • Long-term nephroprotective in >75% of CKD patients

• Calcium Channel Blockers

  • Preferentially dilate afferent arterioles
  • Maintain or increase intraglomerular pressure
  • Dihydropyridines may worsen proteinuria
  • Non-dihydropyridines provide renoprotection

💡 Master This: Glomerular pressure regulation determines disease progression patterns. Efferent arteriolar vasoconstriction (diabetes, hypertension) → hyperfiltration → progressive nephron loss. Afferent arteriolar vasoconstriction (NSAIDs, calcineurin inhibitors) → acute GFR decline → reversible with drug cessation.

Connect these hemodynamic principles through Filtration Selectivity: The Molecular Discrimination Engine to understand how pressure-driven flow enables the precise molecular sorting that separates normal from pathological protein excretion.

🎯 Filtration Selectivity: The Molecular Discrimination Engine

Size-Selective Filtration follows molecular radius relationships:

• Freely Filtered (Molecular Radius <1.8 nm)

  • Inulin: 1.48 nm, 100% filtered
  • Creatinine: 0.4 nm, 100% filtered
  • Urea: 0.26 nm, 100% filtered
  • Glucose: 0.36 nm, 100% filtered
  • Sodium: 0.12 nm, 100% filtered

• Partially Filtered (Molecular Radius 1.8-3.6 nm)

  • Myoglobin: 2.1 nm, 75% filtered
  • β2-microglobulin: 1.7 nm, 70% filtered
  • Light chains: 1.4 nm, 60% filtered
  • Lysozyme: 1.9 nm, 80% filtered

• Minimally Filtered (Molecular Radius >3.6 nm)

  • Albumin: 3.6 nm, <5% filtered
  • Transferrin: 4.0 nm, <2% filtered
  • IgG: 5.5 nm, <1% filtered
  • Fibrinogen: 10.7 nm, <0.1% filtered

📌 Remember: FPMM - Freely filtered (<1.8 nm), Partially filtered (1.8-3.6 nm), Minimally filtered (>3.6 nm), Massively retained (>5.5 nm). The 3.6 nm albumin threshold separates normal from pathological proteinuria.

Charge-Selective Filtration depends on electrostatic interactions:

• Anionic Proteins (Negatively Charged)

  • Albumin: Isoelectric point 4.7, highly anionic at physiological pH
  • Repelled by negatively charged heparan sulfate in GBM
  • Filtration coefficient reduced by 50-70% compared to neutral molecules
  • Enhanced retention through electrostatic repulsion

• Cationic Proteins (Positively Charged)

  • Lysozyme: Isoelectric point 11.0, highly cationic
  • Attracted to negatively charged filtration barrier
  • Increased filtration compared to size-matched neutral molecules
  • Preferentially filtered in minimal change disease

• Neutral Molecules

  • Filtration determined purely by molecular size
  • No charge-based discrimination
  • Inulin serves as ideal neutral marker

Pathological Filtration Patterns:

• Minimal Change Disease

  • Selective proteinuria: >90% albumin
  • Preserved charge selectivity
  • Normal GBM thickness (300-350 nm)
  • Foot process effacement without structural damage
  • Selectivity index typically <10%

• Focal Segmental Glomerulosclerosis

  • Non-selective proteinuria: albumin + IgG
  • Loss of charge and size selectivity
  • GBM thickening (>400 nm)
  • Segmental sclerosis with podocyte loss
  • Selectivity index typically >20%

• Diabetic Nephropathy

  • Progressive loss of selectivity
  • Early: selective albumin excretion
  • Advanced: non-selective with IgG and transferrin
  • GBM thickening correlates with selectivity loss

💡 Master This: Filtration selectivity patterns predict treatment response and prognosis. Selective proteinuria responds to steroids in >90% of children and 70% of adults. Non-selective proteinuria requires immunosuppression and has <50% complete remission rates. Selectivity index guides initial therapy choice.

Clinical Applications of selectivity assessment:

• Urine Protein Electrophoresis

  • Glomerular pattern: albumin >60%
  • Tubular pattern: low molecular weight proteins >40%
  • Mixed pattern: combination suggests advanced disease

• Protein/Creatinine Ratios

  • Albumin/creatinine: <30 mg/g normal
  • Protein/creatinine: <150 mg/g normal
  • Ratio >3.5 g/g defines nephrotic range

Connect this molecular discrimination through Glomerular Pattern Recognition: Clinical-Pathological Correlation to understand how filtration selectivity translates into recognizable clinical syndromes with specific diagnostic and therapeutic implications.

🔍 Glomerular Pattern Recognition: Clinical-Pathological Correlation

Nephrotic Syndrome Recognition ("The Big Leak"):

• Clinical Tetrad (Present in >90% of cases)

  • Proteinuria: >3.5 g/day or protein/creatinine >3.5 g/g
  • Hypoalbuminemia: <3.0 g/dL (normal 3.5-5.0 g/dL)
  • Edema: Dependent, progressing to anasarca
  • Hyperlipidemia: Total cholesterol >250 mg/dL

• Age-Based Disease Probability

  • Children (<16 years)
    • Minimal Change Disease: 85%
    • FSGS: 10%
    • Membranous: <5%
  • Adults (>16 years)
    • FSGS: 35%
    • Membranous: 30%
    • Minimal Change: 25%
    • Diabetic: 10%

• Laboratory Discrimination

  • Selective proteinuria: Albumin >90% of total protein
  • Complement levels: Normal in primary diseases
  • Selectivity index: <10% suggests steroid responsiveness

📌 Remember: PHEL - Proteinuria (>3.5 g/day), Hypoalbuminemia (<3.0 g/dL), Edema (dependent), Lipidemia (cholesterol >250 mg/dL). All four criteria required for nephrotic syndrome diagnosis.

Nephritic Syndrome Recognition ("The Angry Glomerulus"):

• Clinical Pentad

  • Hematuria: Gross or microscopic with dysmorphic RBCs
  • Proteinuria: <3.5 g/day (sub-nephrotic)
  • Hypertension: >140/90 mmHg in >80%
  • Oliguria: <400 mL/day in acute cases
  • Azotemia: Elevated creatinine with reduced GFR

• Urinalysis Patterns

  • RBC casts: Pathognomonic for glomerulonephritis
  • Dysmorphic RBCs: >80% suggests glomerular bleeding
  • Proteinuria: 1-3 g/day (rarely nephrotic range)
  • WBC casts: Inflammatory component

• Disease-Specific Markers

  • Post-infectious GN: Low C3, elevated ASO (>200 IU/mL)
  • IgA Nephropathy: Elevated serum IgA in 50%
  • RPGN: Creatinine doubling in <3 months

Rapid Progressive Glomerulonephritis (RPGN) Recognition:

• Clinical Definition

  • Creatinine doubling within 3 months
  • GFR decline >50% from baseline
  • Oliguria (<400 mL/day) in >70%
  • Crescents on >50% of glomeruli

• Serological Classification

  • Type I (Anti-GBM): 5% of RPGN
    • Linear IgG on immunofluorescence
    • Goodpasture's syndrome with pulmonary involvement
  • Type II (Immune Complex): 45% of RPGN
    • Granular immunofluorescence pattern
    • Lupus, post-infectious, MPGN
  • Type III (Pauci-immune/ANCA): 50% of RPGN
    • Minimal immunofluorescence
    • c-ANCA (Wegener's) or p-ANCA (microscopic polyangiitis)

💡 Master This: RPGN requires immediate recognition and urgent treatment within 24-48 hours to preserve renal function. Plasma exchange is indicated for anti-GBM disease and severe ANCA vasculitis. Delay >1 week reduces renal recovery probability from >80% to <20%.

Diagnostic Algorithm Integration:

• Step 1: Syndrome Classification

  • Nephrotic vs Nephritic vs Mixed
  • Age-appropriate disease probabilities
  • Complement levels and serological markers

• Step 2: Urgency Assessment

  • RPGN requires immediate biopsy and treatment
  • Stable nephrotic allows empirical steroid trial
  • Nephritic needs serological workup first

• Step 3: Biopsy Indications

  • Adults with nephrotic syndrome (except diabetic)
  • Any RPGN presentation
  • Steroid-resistant nephrotic syndrome
  • Nephritic syndrome with unclear etiology

Connect these recognition patterns through Therapeutic Decision Trees: Evidence-Based Treatment Algorithms to understand how accurate syndrome classification directly determines optimal treatment selection and monitoring strategies.

⚖️ Therapeutic Decision Trees: Evidence-Based Treatment Algorithms

Nephrotic Syndrome Treatment Algorithms:

Pediatric Approach (<16 years):

• First-Line: Empirical Prednisone

  • Dose: 2 mg/kg/day (maximum 80 mg/day)
  • Duration: 4-6 weeks full dose
  • Response rate: 85-90% in minimal change disease
  • Taper: 1.5 mg/kg every other day × 4-6 weeks

• Steroid-Resistant (No response at 8 weeks):

  • Biopsy indication: 100% of cases
  • Second-line options:
    • Cyclosporine: 5 mg/kg/day divided BID
    • Mycophenolate: 1200 mg/m²/day divided BID
    • Rituximab: 375 mg/m² weekly × 4 doses

• Frequently Relapsing (≥2 relapses in 6 months):

  • Steroid-sparing agents indicated
  • Levamisole: 2.5 mg/kg every other day
  • Cyclophosphamide: 2 mg/kg/day × 8-12 weeks

Adult Approach (>16 years):

• Biopsy-First Strategy (Recommended in >90%)
  • Exception: Clear diabetic nephropathy
  • Timing: Within 2-4 weeks of presentation
  • Contraindications: Bleeding risk, small kidneys (<9 cm)

RPGN Treatment Protocols:

Anti-GBM Disease (Type I RPGN):

• Plasma Exchange

  • Daily × 14 days or until anti-GBM negative
  • 4-5 L exchanges with 5% albumin replacement
  • Initiate within 24 hours for optimal outcomes
  • Renal recovery: >80% if creatinine <5.7 mg/dL

• Immunosuppression

  • Methylprednisolone: 15 mg/kg × 3 days
  • Cyclophosphamide: 2 mg/kg/day × 3 months
  • Oral prednisone: 1 mg/kg with rapid taper

ANCA-Associated Vasculitis (Type III RPGN):

• Induction Therapy (Severe disease)

  • Cyclophosphamide: 15 mg/kg IV every 2 weeks × 6 doses
  • Methylprednisolone: 15 mg/kg × 3 days, then oral taper
  • Plasma exchange: If creatinine >5.7 mg/dL or pulmonary hemorrhage

• Alternative Induction

  • Rituximab: 375 mg/m² weekly × 4 doses
  • Non-inferior to cyclophosphamide for remission induction
  • Preferred in young patients and relapsing disease

⭐ Clinical Pearl: Timing determines outcomes in RPGN. Treatment within 24 hours achieves renal recovery in >80% of anti-GBM disease and >70% of ANCA vasculitis. Delay >1 week reduces recovery probability to <30%. Dialysis dependence at presentation doesn't preclude aggressive treatment.

Monitoring and Toxicity Management:

• Steroid Monitoring

  • Bone density: Baseline and annual DEXA
  • Glucose: Weekly during high-dose phase
  • Blood pressure: Daily monitoring
  • Infection screening: Opportunistic pathogen awareness

• Cyclophosphamide Monitoring

  • CBC: Weekly during treatment
  • Hemorrhagic cystitis: Mesna prophylaxis
  • Fertility: Sperm banking in males <40 years
  • Malignancy risk: Long-term surveillance

• Calcineurin Inhibitor Monitoring

  • Trough levels: Cyclosporine 100-200 ng/mL
  • Nephrotoxicity: Monthly creatinine
  • Hypertension: >90% develop elevated BP
  • Drug interactions: Extensive CYP3A4 metabolism

💡 Master This: Personalized treatment selection considers age, comorbidities, fertility concerns, and infection risk. Rituximab preferred in young adults to preserve fertility. Mycophenolate avoided in pregnancy. Cyclophosphamide limited to <6 months to minimize malignancy risk. Response monitoring guides treatment duration and maintenance strategies.

Connect these therapeutic algorithms through Advanced Integration: Multi-System Glomerular Mastery to understand how treatment decisions integrate with cardiovascular protection, bone health, infection prevention, and long-term outcome optimization in complex clinical scenarios.

🔗 Advanced Integration: Multi-System Glomerular Mastery

Cardiovascular-Renal Integration:

• Shared Risk Amplification

  • CKD increases cardiovascular mortality by 2-5 fold
  • Proteinuria >1 g/day independently predicts coronary events
  • GFR <60 mL/min equivalent to diabetes for CV risk
  • Nephrotic syndrome creates hypercoagulable state (>10-fold thrombosis risk)

• Integrated Management Strategies

  • ACE inhibitors/ARBs: Dual cardio-renal protection
    • Reduce proteinuria by 30-50%
    • Decrease CV events by 20-25%
    • Target BP: <130/80 mmHg in CKD patients
  • Statin therapy: Universal in nephrotic syndrome
    • Atorvastatin 40-80 mg for LDL <100 mg/dL
    • Reduces CV events by 25% in CKD population
  • Anticoagulation: Consider if albumin <2.5 g/dL
    • Prophylactic anticoagulation in membranous nephropathy
    • Risk-benefit analysis for bleeding vs thrombosis

Bone-Mineral Metabolism Integration:

• CKD-Mineral Bone Disorder (CKD-MBD)

  • Phosphate retention begins at GFR <60 mL/min
  • Secondary hyperparathyroidism develops early
  • Vitamin D deficiency in >80% of CKD patients
  • Fracture risk increased 2-4 fold

• Steroid-Induced Osteoporosis (SIOP)

  • Bone loss: 10-20% in first year
  • Fracture risk increases within 3 months
  • Vertebral fractures most common (>50%)

• Integrated Bone Protection

  • Calcium: 1200-1500 mg/day with vitamin D
  • Vitamin D3: 2000-4000 IU/day (target 25(OH)D >30 ng/mL)
  • Bisphosphonates: Alendronate 70 mg weekly if T-score <-2.5
  • Denosumab: Alternative if GFR <35 mL/min

Infection Prevention Integration:

• Immunodeficiency Mechanisms

  • Nephrotic syndrome: Immunoglobulin losses, complement depletion
  • Steroid therapy: T-cell suppression, neutrophil dysfunction
  • Cytotoxic agents: Bone marrow suppression
  • Rituximab: B-cell depletion for 6-12 months

• Vaccination Strategies

  • Pre-immunosuppression: Live vaccines (MMR, varicella)
  • Annual influenza: Inactivated vaccine only
  • Pneumococcal: PCV13 followed by PPSV23
  • Hepatitis B: Higher doses (40 mcg) with titer monitoring
  • COVID-19: mRNA vaccines with additional doses

• Prophylaxis Protocols

  • PCP prophylaxis: TMP-SMX if prednisone >20 mg × >1 month
  • CMV monitoring: High-risk patients (rituximab, high-dose steroids)
  • Fungal prophylaxis: Consider in prolonged neutropenia

⭐ Clinical Pearl: Infection remains the leading cause of mortality in immunosuppressed glomerular disease patients (>40% of deaths). Proactive vaccination and prophylaxis strategies reduce infection-related mortality by >50%. Live vaccines must be completed >4 weeks before immunosuppression initiation.

Long-term Outcome Optimization:

• Renal Survival Predictors

  • Time to remission: <6 months predicts better outcomes
  • Complete vs partial remission: 10-year survival 90% vs 60%
  • Proteinuria reduction: >50% reduction protective
  • Histological response: Correlates with long-term function

• Quality of Life Integration

  • Steroid toxicity: Weight gain, mood changes, sleep disruption
  • Immunosuppression anxiety: Infection fears, malignancy concerns
  • Dietary restrictions: Sodium, protein, phosphate limitations
  • Exercise capacity: Reduced in >60% of CKD patients

• Transition Planning

  • Pediatric to adult care: Structured transition at age 18-21
  • Pregnancy counseling: Teratogenic drug avoidance
  • Career considerations: Infection risk in healthcare workers
  • End-stage planning: Early transplant evaluation

💡 Master This: Successful glomerular disease management requires anticipatory multi-system care that prevents complications rather than treating them reactively. Cardiovascular protection begins at diagnosis. Bone protection starts with first steroid dose. Infection prevention includes pre-immunosuppression vaccination. Long-term planning addresses fertility, pregnancy, and career implications from disease onset.

Connect this comprehensive integration through Clinical Mastery Arsenal: Rapid Assessment and Decision Tools to synthesize all previous concepts into practical, immediately applicable clinical frameworks for optimal patient care.

🎯 Clinical Mastery Arsenal: Rapid Assessment and Decision Tools

Rapid Syndrome Classification Framework:

📌 The NEPHRON Assessment: Nephrotic (proteinuria >3.5 g/day), Edema pattern, Pressure (hypertension), Hematuria presence, Renal function (GFR), Onset timing, Neurological symptoms. Complete assessment in <5 minutes with >90% diagnostic accuracy.

• 60-Second Triage Protocol
  • Step 1 (10 seconds): Proteinuria quantification
    • >3.5 g/day → Nephrotic pathway
    • <3.5 g/day + hematuria → Nephritic pathway
  • Step 2 (15 seconds): GFR assessment
    • Normal → Primary glomerular disease
    • Reduced → RPGN vs chronic disease
  • Step 3 (15 seconds): Age and comorbidities
    • Child → Empirical steroids (if nephrotic)
    • Adult → Biopsy indication assessment
  • Step 4 (20 seconds): Urgency determination
    • RPGN → Immediate immunosuppression
    • Stable → Systematic workup

Essential Laboratory Arsenal:

Treatment Decision Matrix:

• Nephrotic Syndrome Algorithm

  • Child (<16 years) + Normal complement

    • Immediate: Prednisone 2 mg/kg/day
    • Response assessment: Week 4
    • Biopsy: Only if steroid-resistant

  • Adult (>16 years) + No diabetes

    • Immediate: Renal biopsy within 2-4 weeks
    • Supportive care: ACEi/ARB, diuretics, statins
    • Treatment: Histology-guided therapy

• RPGN Emergency Protocol

  • Hour 0-2: Urgent nephrology consultation
  • Hour 2-6: Serological workup (ANCA, anti-GBM, complement)
  • Hour 6-24: Renal biopsy if stable for procedure
  • Hour 24: Empirical immunosuppression if biopsy delayed

Monitoring Frameworks:

💡 Master This: The 3-6-12 Rule - 3 months for treatment response, 6 months for remission assessment, 12 months for relapse risk determination. Earlier intervention at each timepoint improves long-term outcomes by >30%.

• Response Monitoring Schedule

  • Weekly (Weeks 1-4): Proteinuria, creatinine, side effects
  • Biweekly (Weeks 4-12): Complete response assessment
  • Monthly (Months 3-12): Relapse surveillance
  • Quarterly (Year 1+): Long-term complications

• Toxicity Surveillance

  • Infection monitoring: CBC weekly during induction
  • Bone health: DEXA at baseline and annually
  • Cardiovascular: BP daily, lipids quarterly
  • Malignancy: Age-appropriate screening annually

Prognostic Stratification Tools:

• High-Risk Features (Poor prognosis indicators)

  • Age >60 years at presentation
  • GFR <30 mL/min at diagnosis
  • >50% crescents on renal biopsy
  • Steroid resistance at 8 weeks
  • Frequent relapses (>2 per 6 months)

• Protective Factors (Good prognosis indicators)

  • Age <16 years at onset
  • Selective proteinuria (>90% albumin)
  • Normal GFR at presentation
  • Steroid responsiveness within 4 weeks
  • Complete remission achievement

📌 Remember: RAPID - Recognize syndrome (<60 seconds), Assess urgency (RPGN vs stable), Plan biopsy (adults, steroid-resistant children), Initiate treatment (evidence-based protocols), Determine monitoring (3-6-12 rule). Systematic approach ensures optimal outcomes while minimizing complications.

Emergency Recognition Triggers:

• Immediate Nephrology Consultation

  • Creatinine doubling within 3 months
  • Gross hematuria with RBC casts
  • Nephrotic syndrome with thrombotic complications
  • Pulmonary-renal syndrome
  • Steroid-resistant nephrotic syndrome

• ICU-Level Care Indications

  • Pulmonary edema with oliguria
  • Severe hypertension (>180/120 mmHg)
  • Pulmonary hemorrhage (hemoptysis)
  • Severe electrolyte disturbances
  • Infection in immunosuppressed patients

This clinical mastery arsenal provides the systematic framework for transforming glomerular disease complexity into manageable, evidence-based patient care that optimizes outcomes while ensuring comprehensive safety monitoring and complication prevention.